Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat

Ross Bullock, D. I. Graham, S. Swanson, J. McCulloch

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

The effects of the glutamate α-amino-3-hydroxy 5-methyl-4-isoxazole propionate (AMPA) receptor antagonist LY-293558 in reducing ischemic brain damage have been assessed in halothane-anesthetized cats. Focal cerebral ischemia was produced by permanent occlusion of one middle cerebral artery, and the animals were killed 6 h later. The amount of early irreversible ischemic damage was assessed at 16 predetermined stereotactic planes by an observer blinded to treatment paradigm employed. Treatment with LY-293558 (15 mg/kg i.v., plus infusion of 7 mg/kg/h) initiated 30 min prior to middle cerebral artery occlusion reduced significantly (p < 0.02) the volume of ischemic damage (from 3.423 ± 212 mm3 of the cerebral hemisphere in vehicle-treated cats to 2,822 ± 569 mm3 in LY-293558-treated cats). The present data demonstrate that an AMPA receptor antagonist can reduce focal ischemic damage in a gyrencephalic species in which key physiological variables have been controlled and monitored throughout the postischemic period. These data provide additional support for the clinical evaluation of AMPA receptor antagonists in focal cerebral ischemia in humans.

Original languageEnglish
Pages (from-to)466-471
Number of pages6
JournalJournal of Cerebral Blood Flow and Metabolism
Volume14
Issue number3
StatePublished - May 1 1994
Externally publishedYes

Fingerprint

tezampanel
AMPA Receptors
Neuroprotective Agents
Brain Ischemia
Cats
Middle Cerebral Artery Infarction
Isoxazoles
Propionates
Cerebrum
Halothane
Glutamic Acid
Brain

Keywords

  • Cerebral ischemia
  • Cerebrovascular disease
  • Glutamate

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Endocrinology, Diabetes and Metabolism

Cite this

Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. / Bullock, Ross; Graham, D. I.; Swanson, S.; McCulloch, J.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 14, No. 3, 01.05.1994, p. 466-471.

Research output: Contribution to journalArticle

Bullock, Ross ; Graham, D. I. ; Swanson, S. ; McCulloch, J. / Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. In: Journal of Cerebral Blood Flow and Metabolism. 1994 ; Vol. 14, No. 3. pp. 466-471.
@article{2d119ce212684a0aa1f085560079d19d,
title = "Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat",
abstract = "The effects of the glutamate α-amino-3-hydroxy 5-methyl-4-isoxazole propionate (AMPA) receptor antagonist LY-293558 in reducing ischemic brain damage have been assessed in halothane-anesthetized cats. Focal cerebral ischemia was produced by permanent occlusion of one middle cerebral artery, and the animals were killed 6 h later. The amount of early irreversible ischemic damage was assessed at 16 predetermined stereotactic planes by an observer blinded to treatment paradigm employed. Treatment with LY-293558 (15 mg/kg i.v., plus infusion of 7 mg/kg/h) initiated 30 min prior to middle cerebral artery occlusion reduced significantly (p < 0.02) the volume of ischemic damage (from 3.423 ± 212 mm3 of the cerebral hemisphere in vehicle-treated cats to 2,822 ± 569 mm3 in LY-293558-treated cats). The present data demonstrate that an AMPA receptor antagonist can reduce focal ischemic damage in a gyrencephalic species in which key physiological variables have been controlled and monitored throughout the postischemic period. These data provide additional support for the clinical evaluation of AMPA receptor antagonists in focal cerebral ischemia in humans.",
keywords = "Cerebral ischemia, Cerebrovascular disease, Glutamate",
author = "Ross Bullock and Graham, {D. I.} and S. Swanson and J. McCulloch",
year = "1994",
month = "5",
day = "1",
language = "English",
volume = "14",
pages = "466--471",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat

AU - Bullock, Ross

AU - Graham, D. I.

AU - Swanson, S.

AU - McCulloch, J.

PY - 1994/5/1

Y1 - 1994/5/1

N2 - The effects of the glutamate α-amino-3-hydroxy 5-methyl-4-isoxazole propionate (AMPA) receptor antagonist LY-293558 in reducing ischemic brain damage have been assessed in halothane-anesthetized cats. Focal cerebral ischemia was produced by permanent occlusion of one middle cerebral artery, and the animals were killed 6 h later. The amount of early irreversible ischemic damage was assessed at 16 predetermined stereotactic planes by an observer blinded to treatment paradigm employed. Treatment with LY-293558 (15 mg/kg i.v., plus infusion of 7 mg/kg/h) initiated 30 min prior to middle cerebral artery occlusion reduced significantly (p < 0.02) the volume of ischemic damage (from 3.423 ± 212 mm3 of the cerebral hemisphere in vehicle-treated cats to 2,822 ± 569 mm3 in LY-293558-treated cats). The present data demonstrate that an AMPA receptor antagonist can reduce focal ischemic damage in a gyrencephalic species in which key physiological variables have been controlled and monitored throughout the postischemic period. These data provide additional support for the clinical evaluation of AMPA receptor antagonists in focal cerebral ischemia in humans.

AB - The effects of the glutamate α-amino-3-hydroxy 5-methyl-4-isoxazole propionate (AMPA) receptor antagonist LY-293558 in reducing ischemic brain damage have been assessed in halothane-anesthetized cats. Focal cerebral ischemia was produced by permanent occlusion of one middle cerebral artery, and the animals were killed 6 h later. The amount of early irreversible ischemic damage was assessed at 16 predetermined stereotactic planes by an observer blinded to treatment paradigm employed. Treatment with LY-293558 (15 mg/kg i.v., plus infusion of 7 mg/kg/h) initiated 30 min prior to middle cerebral artery occlusion reduced significantly (p < 0.02) the volume of ischemic damage (from 3.423 ± 212 mm3 of the cerebral hemisphere in vehicle-treated cats to 2,822 ± 569 mm3 in LY-293558-treated cats). The present data demonstrate that an AMPA receptor antagonist can reduce focal ischemic damage in a gyrencephalic species in which key physiological variables have been controlled and monitored throughout the postischemic period. These data provide additional support for the clinical evaluation of AMPA receptor antagonists in focal cerebral ischemia in humans.

KW - Cerebral ischemia

KW - Cerebrovascular disease

KW - Glutamate

UR - http://www.scopus.com/inward/record.url?scp=0028279015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028279015&partnerID=8YFLogxK

M3 - Article

C2 - 8163588

AN - SCOPUS:0028279015

VL - 14

SP - 466

EP - 471

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 3

ER -